ISAL 2019 | Error-corrected DNA sequencing for MRD detection
Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses the use of advanced error-corrected DNA sequencing for the highly sensitive detection of measurable residual disease (MRD). Next-generation sequencing introduces errors, which this ‘next next-generation sequencing’ method corrects for. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up